Discontinuing GLP-1 receptor agonists like Ozempic may significantly increase cardiovascular risks for patients who have benefited from these medications, according to emerging evidence highlighted by USA Today. While these drugs have gained widespread attention for weight loss, their cardiovascular protective effects represent a critical medical benefit that patients and physicians should carefully consider before stopping treatment.
GLP-1 medications, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), have demonstrated substantial cardiovascular benefits in clinical trials, reducing the risk of heart attacks, strokes, and cardiovascular death by up to 20% in some studies. When patients discontinue these medications, they not only risk regaining lost weight but may also lose these protective cardiac effects. Research suggests that many of the metabolic improvements—including better blood sugar control, reduced inflammation, and improved blood pressure—begin to reverse within weeks of stopping the medication.
The concern is particularly acute for patients with existing cardiovascular disease or multiple risk factors who may have experienced significant health improvements while on GLP-1 therapy. Cardiologists are increasingly recognizing that for many patients, these medications may need to be viewed as long-term treatments rather than temporary interventions, similar to how statins or blood pressure medications are prescribed for ongoing cardiovascular protection.
For patients considering discontinuing GLP-1 medications due to cost, side effects, or achievement of weight loss goals, experts recommend thorough discussions with healthcare providers about cardiovascular risk assessment. Alternative strategies, including lifestyle modifications, other medications, or potentially lower maintenance doses of GLP-1s, may help preserve some benefits while addressing concerns about long-term use. The decision to stop these medications should be individualized and carefully weighed against each patient’s specific cardiovascular risk profile.
